Prokar­i­um rais­es $30M, push­es new bac­te­ria im­munother­a­py for blad­der can­cer to clin­ic

UK biotech Prokar­i­um has raised $30 mil­lion as it heads to­ward the clin­ic with a Sal­mo­nel­la im­munother­a­py for blad­der can­cer, where it hopes to chal­lenge a decades-long stan­dard of care known as Bacil­lus Cal­mette-Guérin, or BCG.

Prokar­i­um CEO Kris­ten Al­bright told End­points News the raise would go to­ward two projects: the blad­der can­cer pro­gram, as well as a sec­ond on RNA ther­a­pies de­liv­ered via the Sal­mo­nel­la plat­form, where the biotech has re­cent­ly part­nered with Gink­go Bioworks.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER